Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IMP-Researcher Johannes Zuber wins German Cancer Prize

25.02.2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research. This was announced today at the opening ceremony of the German Cancer Congress in Berlin.

The German Cancer Prize (Deutscher Krebspreis) is one of the most prestigious scientific awards in the German speaking world and annually honours researchers for groundbreaking discoveries in the field of oncology.


IMP Group Leader Johannes Zuber

Copyright: IMP/Fischer

This year's award acknowledges the achievements of Johannes Zuber, whose contributions have shaped the field of functional cancer genetics. Together with his team at the IMP, the physician scientist uses innovative genetic approaches to identify and study genes that are required for the survival of cancer cells and serve as candidate targets for the development of new cancer therapies.

Through developing and applying optimised RNAi-screening methods, Zuber discovered the gene BRD4 as a genetic vulnerability and candidate target for the treatment of acute myeloid leukemia (AML), an aggressive form of blood cancer.

After BRD4 inhibitors have already shown promising effects in AML and other malignancies, his research team could recently identify molecular mechanisms that render leukemia cells resistant to these agents. These insights are of great importance for the future development of BRD4 inhibitors in the clinic.

“This award is a great honour and encouragement to further expand our research in the field of functional cancer genetics”, says Johannes Zuber. He points out that new genetic tools offer fascinating opportunities for finding and probing therapeutic targets such as BRD4: “We are currently witnessing a true revolution in functional genetics, which will enable us to search for better cancer therapies in entirely new ways.”

Johannes Zuber, born 1974 in Dresden, completed his medical studies and a doctoral thesis in molecular cancer research at Berlin’s Charité Medical School in 2003. During his residency in hematology/oncology at the Charité University Hospital, leukemia became the focus of his scientific interest. In 2005, Zuber moved to the US to join Scott Lowe's lab at the renowned Cold Spring Harbor Laboratory, where he developed innovative genetic models to study targeted therapies in leukemia. In 2011, he founded his own lab at the IMP in Vienna.

The German Cancer Prize is endowed with 22,500 Euros and awarded annually by the “Deutsche Krebsgesellschaft” (German Cancer Society) and the “Deutsche Krebsstiftung” (German Cancer Foundation) for groundbreaking work in three categories: experimental research, translational research and clinical research in oncology.

The criteria are exceptional scientific quality and originality of research in the field of oncology. Former awardees include renowned scientists such as Nobel laureate Harald zur Hausen, Peter Krammer, Axel Ullrich or Walter Birchmeier. Johannes Zuber is the first recipient who is affiliated with an institution in Austria.

About the IMP
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 37 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, neurobiology, disease mechanisms and computational biology.

Media Contact at the IMP
Dr. Heidemarie Hurtl
IMP Communications
Research Institute of Molecular Pathology
Dr. Bohr-Gasse 7
A 1030 Vienna
hurtl@imp.ac.at
+43 (0)1 79730 3625

Weitere Informationen:

http://www.imp.ac.at/research/research-groups/zuber-group/
http://www.imp.ac.at/news/press-releases/

Dr. Heidemarie Hurtl | idw - Informationsdienst Wissenschaft

More articles from Awards Funding:

nachricht Ultrasound Connects
13.11.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht Improving the understanding of death receptor functions in cells
07.11.2018 | Goethe-Universität Frankfurt am Main

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>